Olmetor
Generic Name
Olmesartan Medoxomil
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| olmetor 20 mg tablet | ৳ 8.00 | ৳ 80.00 |
Description
Overview of the medicine
Olmetor 20 mg Tablet contains Olmesartan Medoxomil, an angiotensin II receptor blocker (ARB) used to treat high blood pressure (hypertension). It helps to relax blood vessels, allowing blood to flow more easily.
Uses & Indications
Dosage
Adults
The usual starting dose is 20 mg once daily. The dose may be increased to 40 mg once daily if blood pressure is not adequately controlled. Doses above 40 mg do not appear to provide additional benefit.
Elderly
No initial dose adjustment is generally required for elderly patients with normal renal function. For those with severe renal impairment, a lower starting dose might be considered.
Renal_impairment
For patients with moderate to severe renal impairment (creatinine clearance < 40 mL/min), a lower starting dose (e.g., 10 mg once daily) and careful monitoring are recommended. Use is contraindicated in patients with anuria or severe renal impairment who are also taking aliskiren.
How to Take
Take Olmetor 20 mg Tablet orally once daily, with or without food, at approximately the same time each day. Swallow the tablet whole with water.
Mechanism of Action
Olmesartan Medoxomil is a prodrug that is rapidly converted to its active metabolite, olmesartan. Olmesartan selectively blocks the binding of angiotensin II to the AT1 receptor in vascular smooth muscle and other tissues. This inhibition prevents the vasoconstrictor and aldosterone-secreting effects of angiotensin II, leading to vasodilation and reduction in blood pressure.
Pharmacokinetics
Onset
Blood pressure reduction begins within 1-2 hours; maximal reduction generally achieved within 2 weeks of initiation.
Excretion
Approximately 35-50% excreted in urine and 50-65% in bile via hepatic excretion. Renal and hepatic impairment can affect clearance.
Half life
Approximately 13 hours.
Absorption
Rapidly and completely absorbed from the gastrointestinal tract and rapidly converted to active olmesartan by esterase hydrolysis during absorption. Absolute bioavailability is approximately 26%. Peak plasma concentrations are reached within 1-2 hours.
Metabolism
Olmesartan medoxomil is a prodrug; it is completely metabolized to its active form, olmesartan, in the gastrointestinal tract by esterase hydrolysis. Olmesartan itself is not metabolized further.
Side Effects
Contraindications
- Hypersensitivity to olmesartan medoxomil or any component of the formulation.
- Pregnancy (especially 2nd and 3rd trimesters).
- Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment (eGFR < 60 mL/min/1.73 m2).
- Biliary obstruction.
Drug Interactions
Lithium
Increased serum lithium concentrations and lithium toxicity have been reported. Monitor lithium levels.
Aliskiren
Concomitant use is contraindicated in patients with diabetes or moderate to severe renal impairment due to increased risk of hyperkalemia, hypotension, and renal impairment.
Non-steroidal anti-inflammatory drugs (NSAIDs)
May reduce the antihypertensive effect of Olmetor and increase the risk of renal function deterioration, especially in elderly or dehydrated patients.
Potassium-sparing diuretics/Potassium supplements
May increase serum potassium levels, leading to hyperkalemia.
Storage
Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children. Do not freeze.
Overdose
Symptoms of overdose include severe hypotension (low blood pressure), tachycardia (rapid heart rate), or bradycardia (slow heart rate). Treatment is supportive and symptomatic, focusing on maintaining cardiovascular stability. Intravenous fluid administration may be necessary.
Pregnancy & Lactation
Pregnancy: Olmetor is contraindicated during the second and third trimesters of pregnancy due to risks of fetal injury or death. Discontinue use as soon as pregnancy is detected. Lactation: It is not known whether olmesartan is excreted in human milk. Due to the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Side Effects
Contraindications
- Hypersensitivity to olmesartan medoxomil or any component of the formulation.
- Pregnancy (especially 2nd and 3rd trimesters).
- Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment (eGFR < 60 mL/min/1.73 m2).
- Biliary obstruction.
Drug Interactions
Lithium
Increased serum lithium concentrations and lithium toxicity have been reported. Monitor lithium levels.
Aliskiren
Concomitant use is contraindicated in patients with diabetes or moderate to severe renal impairment due to increased risk of hyperkalemia, hypotension, and renal impairment.
Non-steroidal anti-inflammatory drugs (NSAIDs)
May reduce the antihypertensive effect of Olmetor and increase the risk of renal function deterioration, especially in elderly or dehydrated patients.
Potassium-sparing diuretics/Potassium supplements
May increase serum potassium levels, leading to hyperkalemia.
Storage
Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children. Do not freeze.
Overdose
Symptoms of overdose include severe hypotension (low blood pressure), tachycardia (rapid heart rate), or bradycardia (slow heart rate). Treatment is supportive and symptomatic, focusing on maintaining cardiovascular stability. Intravenous fluid administration may be necessary.
Pregnancy & Lactation
Pregnancy: Olmetor is contraindicated during the second and third trimesters of pregnancy due to risks of fetal injury or death. Discontinue use as soon as pregnancy is detected. Lactation: It is not known whether olmesartan is excreted in human milk. Due to the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years from the date of manufacture, specific details on packaging.
Availability
Available in pharmacies and hospitals
Approval Status
DGDA approved (Bangladesh), FDA approved (USA)
Patent Status
Generic versions available
Clinical Trials
Olmesartan medoxomil has undergone extensive clinical trials demonstrating its efficacy and safety in reducing blood pressure in patients with hypertension. Studies have shown it to be effective both as monotherapy and in combination with other antihypertensive agents.
Lab Monitoring
- Periodically monitor serum creatinine and BUN (Blood Urea Nitrogen) to assess renal function.
- Monitor serum potassium levels, especially in patients with renal impairment or those taking potassium-sparing diuretics.
- Regularly monitor blood pressure.
Doctor Notes
- Monitor blood pressure, renal function (serum creatinine, BUN), and serum potassium levels regularly, especially in patients with pre-existing renal impairment, heart failure, or those receiving concomitant potassium-sparing diuretics.
- Advise women of childbearing potential about the fetal toxicity risk and to discontinue if pregnancy is detected.
- Counsel patients on the importance of adherence to therapy and lifestyle modifications.
- Caution in patients with volume depletion or severe congestive heart failure, as initial doses may cause symptomatic hypotension.
Patient Guidelines
- Take the medicine exactly as prescribed by your doctor.
- Do not stop taking Olmetor suddenly without consulting your doctor, even if you feel well, as your blood pressure may rise.
- Inform your doctor if you experience any swelling of your face, lips, tongue, or throat, or difficulty breathing, as these could be signs of a serious allergic reaction (angioedema).
- If you are pregnant or planning to become pregnant, inform your doctor immediately.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
Olmetor may cause dizziness or lightheadedness, especially when initiating treatment or increasing the dose. Patients should be cautioned about driving or operating machinery until they know how Olmetor affects them.
Lifestyle Advice
- Maintain a healthy diet low in sodium and saturated fats.
- Engage in regular physical activity as advised by your doctor.
- Avoid smoking and limit alcohol consumption.
- Monitor your blood pressure regularly at home if recommended by your doctor.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Olmetor Brand
Other medicines available under the same brand name
